Drugs that contain Letermovir

1. List of Prevymis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 2 months from now)

USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 8, 2024

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PREVYMIS family patents

5

European Union

4

United States

3

Germany

3

China

3

Hungary

2

Portugal

2

Malaysia

2

Spain

2

Brazil

2

Colombia

2

New Zealand

2

Norway

2

Mexico

2

Morocco

2

Korea, Republic of

2

Hong Kong

2

South Africa

2

Japan

2

Canada

2

Slovenia

2

Ukraine

2

Israel

2

Poland

2

Chile

2

Australia

2

Denmark

1

Singapore

1

Uruguay

1

Russia

1

Croatia

1

Egypt

1

Philippines

1

Argentina

1

Austria

1

Peru

1

Taiwan, Province of China

1

Honduras

1

Tunisia

1

EA

1

India

1

Lithuania

1

ME

1

RS

1

Ecuador

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic